Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DS-5010 |
Synonyms | |
Therapy Description |
DS-5010 (BOS172738) is a multi-kinase inhibitor that inhibits RET and KDR, which may lead to inhibition of tumor cell growth (Cancer Res 2019;79(13 Suppl):Abstract nr 2199). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DS-5010 | DS5010|DS 5010|BOS172738|BOS-172738|BOS 172738 | RET Inhibitor 53 VEGFR2 Inhibitor 37 | DS-5010 (BOS172738) is a multi-kinase inhibitor that inhibits RET and KDR, which may lead to inhibition of tumor cell growth (Cancer Res 2019;79(13 Suppl):Abstract nr 2199). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03780517 | Phase I | DS-5010 | Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors | Completed | USA | FRA | ESP | BEL | 3 |